Patrick Lamy - Mar 3, 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Mar 3, 2025
Transactions value $
-$28,220
Form type
4
Date filed
3/5/2025, 06:55 PM
Previous filing
Jan 29, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $19.9K +1K +2.99% $19.87 34.5K Mar 3, 2025 Direct F1
transaction AKRO Common Stock Sale -$48.1K -1K -2.9% $48.09 33.5K Mar 3, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -1K -1.26% $0.00 78.2K Mar 3, 2025 Common Stock 83.2K $19.87 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 28, 2024, previously adopted by the Reporting Person.
F2 This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8, 2023.